Novel potent inducer of hexamethylene bis-acetamide inducible protein 1 (HEXIM1)

Novel inhibitor of the phosphorylation of DRP1, stimulating a phenotype suggestive of respiration through mitochondrial normalization and demonstrating activity in Vemurafenib-resistant melanoma in vivo

Novel orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist

Novel TGF-β Signaling Inhibitor

Novel LsrK inhibitor (ID 50 119 μM) agaist antimicrobial resistance (AMR)

Novel inhibitor of Tau aggregation against Tau-related neurodegenerative diseases including Alzheimer's disease (AD)

Master regulator of iron homeostasis, contributing to Swedish mutant APP-induced osteoclastogenesis and trabecular bone loss

Heparin derivative for treatment of thrombotic diseases

Heparan sulfate antagonist

The biosynthetic precursor of gossypol

Cytotoxic peptide, inducing mitotic arrest and abnormal spindle formation

Inhibitor of interleukin-1β-induced MIP-1β production

Natural anti-inflammatory and anti-cancer agent

Anti-inflammatory and anti-cancer agent, disrupting the cooperation of CCAAT-box/enhancer-binding protein beta (C/EBPß) and co-activator p300

Potent inhibitor of the ErbB receptor family (IC50 values are 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2 respectively)

Potent antifungal agent, hosting defense peptide mimic through a membrane-active mechanism

Novel Histone deacetylase (HDAC) inhibotor, displays potent inhibitory activity towards human HDACs and several cancer cells lines

Novel HDAC inhibitor, targeting HDAC2, HDAC3, HDAC4, HDAC5, HDAC7, HDAC8, and HDAC9

Novel Selective Histone Deacetylase 8 (HDAC8) Inhibitor with Anti-Neuroblastoma Activity

First-in-class proteolysis targeting chimera (PROTAC) for selective degradation of histone deacetylase 8 (HDAC8)

Novel highly potent and selective HDAC6 inhibitor with an IC 50 of 2.54 nM and being more than 290- to 3300-fold selective over other HDAC isoforms

Potent and selective HDAC6 inhibitor

Potent and selective HDAC6 inhibitor

Novel HDAC6 isoform-selective inhibitor, increasing the acetylation level of α-tubulin with little effect on the acetylation of histone H3, inducing apoptosis in HL-60 cell by activating caspase 3

Novel potent HDAC6 inhibitor with an IC 50 of 31 nM and excellent HDAC6 selectivity (SI = 338 for HDAC6 over HDAC3), displaying high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC

Novel hHDAC6 inhibitor, having low inhibitory potency over hHDAC1 and hHDAC8, as potential pharmacological tools for idiopathic pulmonary fibrosis (IPF) treatment

Novel potent and selective PROTAC degrader of HDAC6 protein

Novel PROTAC HDAC6 degrader, efficiently and selectively decreased HDAC6 levels in several cell lines, including activated THP-1 cells

High affinity and selective colchicine site tubuline inhibitor amenable to radiolabel with C-11, a positron emitting isotope

Novel Inhibitor of Hepatitis C Virus